#United States #San Jose #Complete Genomics #Swiss Rockets AG #genomic sequencing

Complete Genomics to Be Acquired by Swiss Rockets AG

In a significant development in the biotech arena, Complete Genomics, a leading player in genomic sequencing technology based in the United States, has confirmed a definitive agreement to be acquired by Swiss Rockets AG, a Swiss life sciences group. This transaction, which is subject to customary closing conditions and the approval of MGI shareholders, marks a strategic step aimed at enhancing innovation and expanding market capabilities within the genomics sector.

Enhancing Innovation and Market Reach

The acquisition was announced during a press release on February 23, 2026, highlighting the dual motives behind this move: to scale the innovative pipeline of Complete Genomics and to diversify its manufacturing capacity. Dr. Vladimir Cmiljanovic, the founder and CEO of Swiss Rockets AG, expressed enthusiasm about the move, noting, "Swiss Rockets recognized Complete Genomics' strong position in developing and delivering cost-effective, flexible sequencing solutions. We see an opportunity to accelerate innovation and expand market reach."

Dr. Cmiljanovic's intent is clear: to support Complete Genomics as they broaden their technology portfolio while reinforcing resilience in their supply chain. The acquisition aims not merely to merge operations but to foster a collaborative environment that prioritizes advancements in genomic research.

Following the closure of the deal, Swiss Rockets will maintain full ownership of Complete Genomics while allowing it to continue its operations under its established management team. This leadership will oversee daily operations, product strategy, software development, and customer relationships, ensuring that the company's essence remains intact while benefiting from Swiss Rockets’ strategic guidance.

A Vision for the Future

This acquisition represents a pivotal moment for Complete Genomics, positioning the company for its next growth phase. Dr. Rade Drmanac, founder of Complete Genomics, remarked, "Swiss Rockets shares our long-term vision for sequencing innovation and supports our strategy to expand product adoption, strengthen operational independence, and progressively diversify our manufacturing and supply chain footprint."

The rationale behind the deal extends beyond mere acquisition; it reflects a deeper strategic vision. Swiss Rockets is already recognized for its innovation in targeted cancer therapies and next-generation vaccines. By acquiring Complete Genomics, Swiss Rockets aims to complement its offerings with cutting-edge next-generation sequencing (NGS) technology, thus broadening access to precision medicine and facilitating the development of new diagnostics and therapies.

Assurances for Customers

For existing customers, the acquisition promises continuity amidst the changes. Complete Genomics reassures that there will be no disruption in the products, services, software, or data handling practices that customers have come to rely on. All existing customer agreements will remain unchanged, thereby providing stability in service and support.

Moreover, the U.S.-based software development team will continue to manage and maintain the software on Complete Genomics sequencers, ensuring that users continue to receive updates and support seamlessly. This commitment to customer satisfaction underscores the value placed on established relationships and trust built over the years.

About Complete Genomics

Founded in 2005, Complete Genomics has made a name for itself as a pioneering force in the field of genomic sequencing, having provided end-to-end DNA sequencing platforms, reagents, and software for various research applications. With a track record of supporting over 10,900 scientific publications worldwide, it stands out in advancing high-throughput, cost-effective sequencing innovation.

For more information about the company, you can visit Complete Genomics.

About Swiss Rockets AG

Swiss Rockets AG serves as an incubator and accelerator for life sciences, particularly in biotech and precision healthcare. Focused on oncology, its portfolio includes a variety of therapies and vaccines, showcasing a comprehensive approach to healthcare innovation across various stages of clinical development.

In conclusion, the acquisition of Complete Genomics by Swiss Rockets AG on the horizon signals an exciting future for both entities, promising advancements that could shape the genomic landscape and ultimately enhance the capabilities within precision medicine.